Neptune Wellness Solutions Inc (NEPT)

[Karry]

NTB posssibly doubling + stock dividends for Neo.

Equity Briefing: Exec hints at doubling revenues and a possible spin-off dividend for NEPT investors

* Reuters is not responsible for the content in this press release.





Wed Apr 25, 2012 2:46pm EDT



Wael Massrieh, the VP of Scientific affairs for Neptune Technologies and Bioresources (NASDAQ: NEPT), in a videotaped interview on Wednesday hinted that his firm will see a substantial increase in revenues due to their plant expansion roll-out.

"Our previous capacity was 150 metric tons before we started the expansion. The capacity is actually going to go up to 300 metric tons by the end of the year. So that actually means that we're going to end up doubling our revenues by the end of the year if the whole capacity is capitalized on.

Neptune has considerable ownership stakes in the subsidiary Acasti Pharma (TSX:APO). That intriguing biotech spin-offs seeking to develop and exploit pharmaceutical applications for marine omega-3 phospholipid bioactive ingredients in huge multi-billion dollar markets, each with vast unmet needs.

Massrieh also hinted that Neptune shareholders may soon be given an opportunity to own shares of a new biotech spin-off shortly.

"This company is actually called NeuroBioPharm and it will be spun off in the next couple of months," explained and it's going to follow a very similar strategy to how Acasti was successfully spun out. The idea there is basically is that the Neptune shareholders will actually have access to ownership of NeuroBioPharm before it actually even starts trading publicly."

Volume in the stock was trading at levels much higher than average, on Wednesday with official announcements set to follow.